Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Determine the Efficacy and Safety of Allogeneic Human Chondrocytes Expressing TGF-β1 (TissueGene-C) in Patients With Grade 3 Chronic Degenerative Joint Disease of the Knee

NCT01221441 is registered in ClinicalTrials.gov with Kolon TissueGene, Inc. as lead sponsor.

NCT NCT01221441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01221441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Determine the Efficacy and Safety of Allogeneic Human Chondrocytes Expressing TGF-β1 (TissueGene-C) in Patients With Grade 3 Chronic Degenerative Joint Disease of the Knee
Lead sponsor
Kolon TissueGene, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
October 31, 2014
Enrollment
102 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, knee